# Brain Mechanisms of Cognitive Response to Pharmacotherapy in Opioid Use Disorder

> **NIH NIH R61** · UNIVERSITY OF PENNSYLVANIA · 2021 · $405,265

## Abstract

Relapse prevention is the greatest challenge in opioid use disorder (OUD) treatment. We
propose to elucidate the mechanisms of response to OUD by investigating the effects of OUD
pharmacotherapy on the neurocognitive domains instrumental to relapse. We shall use
previously validated neurocognitive probes, functional Magnetic Resonance Imaging (fMRI),
and the novel extended-release injectable preparation (Brixadi ®) of the opioid partial agonist
buprenorphine (XRBUP) and approved antagonist naltrexone (XRNTX), in OUD patients.
Using two medications with opposing opioid receptor action will allow a comprehensive
evaluation of the response mechanisms to relapse prevention medications in OUD. The R61
phase (Aim 1) will search for treatment effects in the domains of executive function, incentive
salience and emotion regulation and the interaction that will indicate a difference between the
two medications. Differences in at least two domains, with an effect size that is at least small
(Cohen's d>0.2), will serve as a milestone for advance to the R33 phase (Aim 2). The R33
phase will test the significance of the interactions examined in the R61 phase and the ability of
the brain signal to explain relapse defined by % of opioid-positive urine tests and adherence to
the study treatments. Participants will be treatment-seeking OUD patients who will receive
three monthly XRNTX or XRBUP injections yielding approximately 100 days of treatment and
have weekly urine toxicology monitoring. In the R61 phase, 40 treatment-seeking OUD
patients who completed detoxification will be randomly assigned to XRNTX or XRBUP. If the
milestone is met, the R33 phase will randomize 160 participants. Logistic regression will be
used to test the explanatory value of the brain signal in modeling relapse vulnerability, identify
variables that differentiate treatment groups, test the explanatory value of integrated brain-
behavior models of relapse vulnerability, identify differences in variable loading between
treatment groups, and explore the potential mechanism of individual variability in treatment
outcomes. The proposal would be the first neural systems' level investigation of the cognitive
effects of the next generation extended-release preparation of buprenorphine and naltrexone
to explain the individual heterogeneity of OUD treatment response and failure. This project can
advance the theory and personalized treatment of OUD by elucidating the brain mechanisms
of vulnerability to relapse in OUD and SUD in general.

## Key facts

- **NIH application ID:** 10213487
- **Project number:** 1R61DA051625-01A1
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** James W Loughead
- **Activity code:** R61 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $405,265
- **Award type:** 1
- **Project period:** 2021-09-30 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10213487

## Citation

> US National Institutes of Health, RePORTER application 10213487, Brain Mechanisms of Cognitive Response to Pharmacotherapy in Opioid Use Disorder (1R61DA051625-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10213487. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*